Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma: Erratum
Bo Wang, Fang-Zheng Qi, Ping Chen, Luo-Meng Qian, Hui-Shan Su, Yang Wang, Chen-Hui Wang, Ya-Xin Hou, Qing Zhang, Ding Li, Zhe-Sheng Chen, Si-He Zhang
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer, Hypoxia, and Metabolism · Nanoplatforms for cancer theranostics · Hepatocellular Carcinoma Treatment and Prognosis
In the process of checking the raw data, the authors noticed several inadvertent mistakes occurring in Figure 6E and Figure 7I&7J. During the preparation of these panels, the representative images showing results of H&E staining assays (Figure 6E and Figure 7I), and TUNEL staining assays (Figure 7J) were pasted and placed by mistake. The correct result should be as shown below. The authors apologize for these oversights and declare that this correction does not affect the description, interpretation, or conclusions detailed in the original paper.